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received treatment with amlodipine while 14 received
treatment with other antihypertensives, primarily beta
blockers (n¼11). A signiﬁcant difference was not found in
the primary or secondary endpoints, which assessed safety
and efﬁcacy between the treatment groups. Signiﬁcant
differences were found between those with and those
without cyclosporine-induced hypertension. Patients with
cyclosporine-induced hypertension had a longer mean
length of stay, 35.4 days (18-109) as compared to 24.1 days
(7-74). Zero of the 9 patients who received amlodipine
prior to and during the BMT admission went on to expe-
rience cyclosporine-induced hypertension. Available
results, although not robust, suggest that safety and efﬁ-
cacy are similar in allogeneic BMT patients whether they
receive amlodipine or another antihypertensive to treat
cyclosporine-induced hypertension. However, the data
provided did identify that those patients receiving amlo-
dipine prior to and during their bone marrow transplant
were less likely to experience cyclosporine-induced
hypertension.545
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Background: Peri-transplant iron overload (IOL) has been
associated with increased non-relapse morbidity and
mortality in patients receiving hematopoietic stem cell
transplant (HSCT). Iron chelation therapy (ICT) with
deferoxamine or deferasirox, and phlebotomy remain the
major therapeutic options for reducing IOL in HSCT recip-
ients, though the role of ICT in these patients, particularly
in the post-transplant period, has not been clearly deﬁned.
The aim of this study was to evaluate the impact of
post-transplant ICT on outcomes up to day +100 in allo-
geneic HSCT, and to assess the tolerability of post-trans-
plant ICT.
Methods: A retrospective medical record review of 29
patients who underwent allogeneic HSCT from March 2009
to October 2011 at a 779-licensed bed, urban academic
medical center was conducted. Inclusion criteria were age 
18 years and serum ferritin level  1000 ng/mL within 3
months prior to transplant. Exclusion criteria were mis-
matched or cord blood transplant, and ICT initiated in the
pre-transplant period or after day +50. Patients were divided
into 2 groups: those who received  1 dose of deferoxamine
or deferasirox post-transplant up to day +50 (ICT group), and
those who had never received ICT (non-ICT group). The
primary endpoint was clinically signiﬁcant liver dysfunction
up to day +100.
Results: Of the 29 patients evaluated, 22 were in the non-
ICT group and 7 in the ICT group (6 received deferoxamine
1000 mg IV daily, 1 received deferasirox 2000 mg orally
daily; median duration of ICT, 24 days). There were no
statistically signiﬁcant differences between the groups in
demographic or transplant characteristics, though there
was a longer median time from diagnosis to transplant
(417 vs. 238 days, P ¼ .37) and a higher median pre-
transplant ferritin level (2910 vs. 1673 ng/mL, P ¼ .38) in
the ICT group compared to the non-ICT group. Four
patients experienced clinically signiﬁcant liver dysfunc-
tion, with 3 patients (13.6%) in the non-ICT group and 1patient (14.3%) in the ICT group (P ¼ .99). There were no
signiﬁcant differences in other post-transplant outcomes
evaluated, including change in ferritin level, bloodstream
infection, and death. Of the 7 ICT patients, 71.4% experi-
enced acute kidney injury that required interruption or
discontinuation of ICT.
Conclusions: ICT in the immediate post-transplant period
did not improve post-transplant outcomes and was not well
tolerated. Alternative strategies for the administration of
pre- or peri-transplant ICT in HSCT recipients are recom-
mended.546
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Background: Linezolid (LZ) is an oxazolidinone antimicro-
bial often used to treat resistant gram-positive bacteria and
has been associated with mild, reversible, time-dependent
myelosuppression, including thrombocytopenia (common),
anemia (common), leukopenia, and pancytopenia. Gener-
ally, these effects occur with treatment durations of  14
days. Patients with underlying hematologic abnormalities
may be more at risk for the development of LZ-induced
myelosuppression, but this is controversial. We hypothe-
sized that LZ use before engraftment may delay hemato-
poietic recovery following stem cell transplant (SCT), and
performed a matched controlled analysis to investigate this
hypothesis.
Methods: With institutional review board approval, we
retrospectively evaluated 24 patients who received LZ and
compared them to 60 controls who did not receive LZ from 1/
1/1997 to 1/1/2010. Our SCT database was utilized to ﬁnd
matched controls and matching was based on: diagnosis;
transplant type; cell source; transplant conditioning
regimen; and age +/- 10 years. Patients in the LZ group were
included if LZ was administered at any time from day
0 through engraftment of white cells but for a minimum of
72 consecutive hours. Patients 1 year of age or older were
included. The datawere analyzed for the effects of LZ on time
to neutrophil (ANC > 500 for 3 days) and platelet engraft-
ment (platelet count > 20,000 for 7 days without trans-
fusion), and the cumulative incidence of engraftment of both
neutrophil and platelets within the ﬁrst 100 days post-
transplant.
Results: The LZ and control groups were similar with
respect to age (median 44 vs. 41 years), gender (50% vs. 58%
male and 50% vs. 42% female), diagnosis (29% vs. 25% had
AML/MDS), cell source (67% vs. 63% apheresis product),
transplant type (67% vs. 63% allogeneic), ablative vs. non-
ablative conditioning (79% vs. 83% myeloablative), and cell
dose (median CD34 dose 4.52 x 106/kg vs. 4.34 x 106/kg).
Median time to neutrophil engraftment was the same for LZ
and control groups (12 days). The median time to neutro-
phil plus platelet engraftment for LZ group and control
group was 50 days (11 patients censored) vs. 15.5 days (10
patients censored). Neutrophil engraftment failure occurred
